RBC maintains DexCom stock Outperform rating, $100 target

RBC Capital reiterated an Outperform rating and $100 price target for DexCom (DXCM) after a Non-Deal Roadshow, citing underestimated growth potential driven by expanded PBM coverage expected to reach 6 million lives by 2025 and increasing profitability with mid-60s gross margins and OpEx leverage. This positive outlook aligns with InvestingPro data indicating undervaluation and a strong buy consensus, projecting 14% revenue growth for FY25. While DexCom's Q1 revenue beat estimates, adjusted EPS slightly missed, and analyst price targets vary, the company's reaffirmed 2025 revenue guidance of $4.60 billion and $2.7 billion in cash position it favorably for future growth.

Analysis

RBC Capital Markets has reaffirmed its Outperform rating and $100 price target for DexCom (NASDAQ:DXCM), citing an underappreciation by the market of the company's significant growth potential and its capacity to surpass its 2025 financial guidance. This perspective is reinforced by InvestingPro data, which indicates DexCom is trading below its Fair Value, alongside a strong analyst buy consensus, a projected 14% revenue growth for FY2025, and an impressive 22% five-year revenue CAGR. Key catalysts for growth include an unprecedented expansion in U.S. Pharmacy Benefit Manager (PBM) coverage, expected to encompass approximately 6 million lives by the end of 2025, and enhanced profitability driven by targeted mid-60s gross margins and 100-200 basis points of annual operating expense leverage; current gross margins stand at 59.43% according to InvestingPro, and DexCom has guided to approximately 62% non-GAAP gross profit margin for the current year. DexCom's first-quarter revenue of $1.04 billion exceeded estimates, marking a 12% year-over-year increase (14% organic), although adjusted earnings per share of $0.32 were marginally below expectations, and international revenue growth did not meet consensus. Analyst sentiment remains predominantly positive despite varied price targets—BTIG at $109, Canaccord Genuity at $106, and Bernstein at $88 (maintaining Outperform)—with factors such as robust U.S. sales, potential in the Type 2 non-insulin market, and a $750 million share repurchase program being highlighted. The company has reiterated its 2025 revenue guidance of $4.60 billion and maintains a strong financial footing with $2.70 billion in cash, cash equivalents, and marketable securities.

Key Decisions for Investors

• Investors should assess DexCom's current valuation relative to its articulated growth drivers, including the significant PBM coverage expansion and the potential to outperform its 2025 financial targets.
• Closely monitor the execution of the PBM expansion, progress towards targeted gross margins and operating expense leverage, and the performance trajectory of international sales which showed some softness in Q1.
• Consider the acknowledged risks, such as market competition and supply chain challenges, when evaluating the company's reaffirmed guidance and long-term prospects.
• The active $750 million share repurchase program should be viewed as a positive indicator of management's confidence and a potential support for shareholder value.